The knowns and unknowns of the immunopathogenesis of tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 11, 2012, Pages 1424-1432

  Ottenhoff, Tom H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunopathogenic mechanisms; Immunopathology; Mycobacterium tuberculosis

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; REGION OF DIFFERENCE 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; BCG VACCINATION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; COMORBIDITY; HELPER CELL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFECTION RISK; LUNG TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENESCENCE; TH1 CELL; TH17 CELL; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOUS MENINGITIS;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84867198092     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0479     Document Type: Review

References (91)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
2. Ottenhoff T H, Kaufmann S H. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8: e1002607.
3. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021. (Pubitemid 36548927)
4. Ottenhoff T H, Verreck F A, Lichtenauer-Kaligis E G, Hoeve M A, Sanal O, van Dissel J T. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002; 32: 97-105. (Pubitemid 34977203)
5. Keane J, Gershon S, Wise R P, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
6. Cobat A, Gallant C J, Simkin L, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med 2009; 206: 2583-2591.
7. Rose D N, Schechter C B, Adler J J. Interpretation of the tuberculin skin test. J Gen Intern Med 1995; 10: 635-642.
8. Urdahl K B, Shafiani S, Ernst J D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 2011; 4: 288-293.
9. Wolf A J, Desvignes L, Linas B, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008; 205: 105-115. (Pubitemid 351185719)
10. Reiley W W, Calayag M D, Wittmer S T, et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci USA 2008; 105: 10961-10966.
11. Gallegos A M, Pamer E G, Glickman M S. Delayed protection by ESAT-6-specific effector CD4+ T-cells after airborne M. tuberculosis infection. J Exp Med 2008; 205: 2359-2368.
12. Gutierrez M G, Master S S, Singh S B, Taylor G A, Colombo M I, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753-766. (Pubitemid 40017683)
13. Deretic V. Autophagy as an immune defense mechanism. Curr Opin Immunol 2006; 18: 375-382. (Pubitemid 43947574)
14. Rohde K, Yates R M, Purdy G E, Russell D G. Mycobacterium tuberculosis and the environment within the phagosome. I mmunol Rev 2007; 219: 37-54. (Pubitemid 47390002)
15. Sahiratmadja E, Alisjahbana B, de Boer T, et al. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 2007; 75: 820-829. (Pubitemid 46203445)
16. van der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007; 129: 1287-1298. (Pubitemid 46962098)
17. Ottenhoff T H. New pathways of protective and pathological host defense to mycobacteria discovered in tuberculosis and leprosy. Trends Microbiol 2012; 20: 419-428.
18. Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 2012; 12: 352-366.
19. Dorhoi A, Reece S T, Kaufmann S H. For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev 2011; 240: 235-251.
20. Casanova J L, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002; 20: 581-620. (Pubitemid 34293435)
21. Ottenhoff T H, Neuteboom S, Elferink D G, de Vries R R. Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients. J Exp Med 1986; 164: 1923-1939. (Pubitemid 17217974)
22. Geluk A, Bloemhoff W, de Vries R R, Ottenhoff T H. Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. Eur J Immunol 1992; 22: 107-113.
23. Ladel C H, Daugelat S, Kaufmann S H. Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knockout mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 1995; 25: 377-384.
24. Egen J G, Rothfuchs A G, Feng C G, Horwitz M A, Sher A, Germain R N. Intravital imaging reveals limited antigen presentation and T-cell effector function in mycobacterial granulomas. Immunity 2011; 34: 807-819.
25. Khader S A, Bell G K, Pearl J E, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369-377. (Pubitemid 46745412)
26. Cooper A M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27: 393-422.
27. Okamoto Y Y, Umemura M, Yahagi A, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184: 4414-4422.
28. Cruz A, Fraga A G, Fountain J J, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207: 1609-1616.
29. Torrado E, Robinson R T, Cooper A M. Cellular response to mycobacteria: balancing protection and pathology. Trends Immunol 2011; 32: 66-72.
30. Ottenhoff T H, Lewinsohn D A, Lewinsohn D M. Human CD4 and CD8 T-cell responses to Mycobacterium tuberculosis: antigen specificity, function, implications and applications. In: Kaufmann S H E, Britton W J, eds. Handbook of tuberculosis. Weinheim, Germany: Wiley-VCH Verlag, 2008: pp 119-156.
31. Schaible U E, Winau F, Sieling P A, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003; 9: 1039-1046. (Pubitemid 37021784)
32. Winau F, Weber S, Sad S, et al. Apoptotic vesicles crossprime CD8 T-cells and protect against tuberculosis. Immunity 2006; 24: 105-117. (Pubitemid 43077204)
33. Levine B, Mizushima N, Virgin H W. Autophagy in immunity and inflammation. Nature 2011; 469: 323-335.
34. Deretic V. Autophagy in infection. Curr Opin Cell Biol 2010; 22: 252-262.
35. Joosten S A, van Meijgaarden K E, van Weeren P C, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 2010; 6: e1000782.
36. Heinzel A S, Grotzke J E, Lines R A, et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T-cells. J Exp Med 2002; 196: 1473-1481. (Pubitemid 35424941)
37. Gold M C, Cerri S, Smyk-Pearson S, et al. Human mucosal associated invariant T-cells detect bacterially infected cells. PLoS Biol 2010; 8: e1000407.
38. Cohen N R, Garg S, Brenner M B. Antigen presentation by CD1 lipids, T-cells, and NKT cells in microbial immunity. Adv Immunol 2009; 102: 1-94.
39. Grotzke J E, Harriff M J, Siler A C, et al. The Mycobacterium tuberculosis phagosome is a HLA-I processing competent organelle. PLoS Pathog 2009; 5: e1000374.
40. Hernandez-Pando R, Jeyanathan M, Mengistu G, et al. Persistence of DNA from Mycobacterium tuberculosis in superfi cially normal lung tissue during latent infection. Lancet 2000; 356: 2133-2138.
41. Stenger S, Hanson D A, Teitelbaum R, et al. An antimicrobial activity of cytolytic T-cells mediated by granulysin. Science 1998; 282: 121-125. (Pubitemid 28471143)
42. Caccamo N, Meraviglia S, La M C, Guggino G, Dieli F, Salerno A. Phenotypical and functional analysis of memory and effector human CD8 T-cells specific for mycobacterial antigens. J Immunol 2006; 177: 1780-1785. (Pubitemid 44092515)
43. Lewinsohn D A, Winata E, Swarbrick G M, et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 2007; 3: 1240-1249. (Pubitemid 47510277)
44. Commandeur S, van Meijgaarden K E, Lin M Y, et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. Clin Vaccine Immunol 2011; 18: 676-683.
45. Smith S M, Dockrell H M. Role of CD8 T-cells in mycobacterial infections. Immunol Cell Biol 2000; 78: 325-333. (Pubitemid 30655558)
46. Ab B K, Kiessling R, Van Embden J D, et al. Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T-lymphocytes as well as non-specific non-restricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein. Eur J Immunol 1990; 20: 369-377. (Pubitemid 20082407)
47. Caccamo N, Guggino G, Meraviglia S, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 2009; 4: e5528.
48. Maglione P J, Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 2009; 39: 676-686.
49. Berry M P, Graham C M, McNab F W, et al. An interferoni nducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
50. Maertzdorf J, Repsilber D, Parida S K, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011; 12: 15-22.
51. Maertzdorf J, Weiner J III, Mollenkopf H J, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012; 109: 7853-7858.
52. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl K B. Pathogen-specific regulatory T-cells delay the arrival of effector T-cells in the lung during early tuberculosis. J Exp Med 2010; 207: 1409-1420.
53. Kursar M, Koch M, Mittrucker H W, et al. Cutting edge: regulatory T-cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 2007; 178: 2661-2665. (Pubitemid 46333142)
54. Joosten S A, van Meijgaarden K E, Savage N D, et al. Identification of a human CD8+ regulatory T-cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 2007; 104: 8029-8034. (Pubitemid 47185870)
55. Joosten S A, Ottenhoff T H. Human CD4 and CD8 regulatory T-cells in infectious diseases and vaccination. Hum Immunol 2008; 69: 760-770.
56. Hesseling A C, Marais B J, Gie R P, et al. The risk of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 2007; 25: 14-18. (Pubitemid 44855247)
57. Andersen P, Doherty T M. The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3: 656-662. (Pubitemid 41052152)
58. Darrah P A, Patel D T, De Luca P M, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843-850. (Pubitemid 47038186)
59. Kagina B M, Abel B, Scriba T J, et al. Specific T-cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182: 1073-1079.
60. Sutherland J S, Adetifa I M, Hill P C, Adegbola R A, Ota M O. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009; 39: 723-729.
61. Caccamo N, Guggino G, Joosten S A, et al. Multifunctional CD4(+) T-cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40: 2211-2220.
62. Smith S G, Lalor M K, Gorak-Stolinska P, et al. Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 2010; 11: 35.
63. Netea M G, Quintin J, van der Meer J W. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011; 9: 355-361.
64. Potian J A, RafiW, Bhatt K, McBride A, Gause W C, Salgame P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 2011; 208: 1863-1874.
65. Ottenhoff T H. Overcoming the global crisis: 'yes, we can', but also for TB . . . ? Eur J Immunol 2009; 39: 2014-2020.
66. Lin M Y, Ottenhoff T H. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem 2008; 389: 497-511. (Pubitemid 351874191)
67. Leyten E M, Lin M Y, Franken K L, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006; 8: 2052-2060. (Pubitemid 44311602)
68. Ottenhoff T H, Ellner J J, Kaufmann S H. Ten challenges for TB biomarkers. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S17-S20.
69. Scriba T J, Kalsdorf B, Abrahams D A, et al. Distinct, specific IL-17- and IL-22-producing CD4+ T-cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008; 180: 1962-1970.
70. Lalor M K, Smith S G, Floyd S, et al. Complex cytokine profi les induced by BCG vaccination in UK infants. Vaccine 2010; 28: 1635-1641.
71. Plantinga T S, Johnson M D, Scott W K, et al. Human genetic susceptibility to Candida infections. Med Mycol 2012; Jun 4. [Epub ahead of print]
72. Lowe D M, Redford P S, Wilkinson R J, O'Garra A, Martineau A R. Neutrophils in tuberculosis: friend or foe? Trends Immunol 2012; 33: 14-25.
73. Blomgran R, Desvignes L, Briken V, Ernst J D. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T-cells. Cell Host Microbe 2012; 11: 81-90.
74. Jeyanathan M, Heriazon A, Xing Z. Airway luminal T-cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol 2010; 31: 247-252.
75. Jeyanathan M, Mu J, McCormick S, et al. Murine airway luminal anti-tuberculosis memory CD8 T-cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am J Respir Crit Care Med 2010; 181: 862-872.
76. Ronan E O, Lee L N, Beverley P C, Tchilian E Z. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 2009; 4: e8235.
77. Tchilian E Z, Ronan E O, de Lara C, et al. Simultaneous immunization against tuberculosis. PLoS ONE 2011; 6: e27477.
78. Lee L N, Ronan E O, de Lara C, et al. CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect Immun 2011; 79: 3328-3337.
79. Keane J, Remold H G, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 2000; 164: 2016-2020. (Pubitemid 30108758)
80. Divangahi M, Desjardins D, Nunes-Alves C, Remold H G, Behar S M. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 2010; 11: 751-758.
81. Tobin D M, Roca F J, Oh S F, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148: 434-446.
82. Tsenova L, Bergtold A, Freedman V H, Young R A, Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci USA 1999; 96: 5657-5662. (Pubitemid 29234674)
83. Tsenova L, Sokol K, Freedman V H, Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998; 177: 1563-1572. (Pubitemid 28243580)
84. Tobin D M, Vary J C Jr, Ray J P, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010; 140: 717-730.
85. Martin-Blondel G, Mars L T, Liblau R S. Pathogenesis of the immune reconstitution inflammatory syndrome in HIVi nfected patients. Curr Opin Infect Dis 2012; 25: 312-320.
86. Meintjes G, Lawn S D, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523. (Pubitemid 352005824)
87. Wilkinson K A, Seldon R, Meintjes G, et al. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009; 180: 674-683.
88. Mahnke Y D, Greenwald J H, DerSimonian R, et al. Selective expansion of polyfunctional pathogen-specific CD4(+) T-cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012; 119: 3105-3112.
89. Meintjes G, Wilkinson K A, Rangaka M X, et al. Type 1-helper T-cells and FoxP3-positive T-cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008; 178: 1083-1089.
90. Tadokera R, Meintjes G, Skolimowska K H, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 2011; 37: 1248-1259.
91. Finke J S, Shodell M, Shah K, Siegal F P, Steinman R M. Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol 2004; 24: 647-652. (Pubitemid 40933116)